Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.
Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer. This story matters for Finance & Markets readers tracking finance. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. InvestorsWire curates and briefs the finance & markets stories that matter. Our editorial policy →